Political observers across the spectrum have long expected Obamacare to be high on Congress’ list of changes it wants made, but the speed of repeal…
Category: Politics & Business
Starting January 1, people who pay the highest out-of-pocket prices for insulin, such as those who pay full retail price at the pharmacy, may directly…
When Bresch talked about drug prices and access existing “in a balance,” she was referring to what the pharmaceutical industry calls value-based pricing.
In its May bulletin to healthcare providers, UnitedHealthcare (@myUHC) announced that, starting July 1st 2016, Medtronic would be its “preferred” in-network provider of insulin pumps for its adult customers with Type 1 diabetes. This means that, with a few exceptions, if you’ve got Type 1 diabetes and health insurance from United, your next pump is going to be Medtronic. And since United is the nation’s largest insurance company, it’s conceivable that other insurance companies will follow suit.
T1International works alongside people with diabetes around the world to advocate for access to diabetes supplies. The charity is currently running their Insulin for Syrians campaign, encouraging people to donate money that will be used to provide insulin and diabetes supplies to families in Aleppo and other locations in Syria where aid has been cut off.
I may have been very late to the astonishing price increase of Glumetza, but I am, by coincidence, among the first to report that the generic price is almost as ridiculous. My bill, $14,009.23, was for the generic, available, as promised, in February 2016 and manufactured by Lupin, an Indian pharmaceutical company that is the sixth largest maker of generics in the world.
Sanofi and the Google life sciences team announced that they are collaborating to improve care and outcomes for people with type 1 and type 2 diabetes. The collaboration will pair Sanofi's leadership in diabetes treatments and devices with Google's expertise in analytics, miniaturized electronics and low power chip design.
Asante Solutions announced that it is ceasing all business operations and will no longer sell or support the Asante Snap Insulin Pump. This means all current Asante Snap Insulin Pump users will soon need to transition to a new insulin pump.
JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, and Tidepool, a Silicon Valley-based non-profit organization committed to reducing the burden of T1D, announced a partnership supported by JDRF funding for data access technology for people with T1D who use insulin pumps and continuous glucose monitors (CGMs) through a device agnostic cloud platform.
Novo Nordisk has decided to discontinue all its research and development (R&D) activities within inflammatory disorders while increasing efforts within diabetes prevention and treatment, obesity and diabetes complications.
The decision to discontinue all R&D within inflammatory disorders follows a review of Novo Nordisk's strategic position in the therapeutic area after...